Weekly Digest: China Healthcare Industry Investment Report (20250113)

【Neuroinflammation Small Molecule Drugs】GuangZhou GaoLing Pharmaceutical Company, Ltd. is an innovative drug development company rooted in China and oriented globally, driven by independent research and development. It is committed to developing breakthrough innovative drugs for treating critical diseases that endanger human life or health and address urgent unmet clinical needs. The company is currently developing small molecule drugs for autoimmune diseases and inflammation, with global intellectual property rights. These drugs have entered Phase I and II clinical trials in both China and the U.S. The leading project is a highly selective TYK2/JAK1 dual inhibitor capable of effectively crossing the blood-brain barrier. The company's R&D team consists of renowned drug design scientists with over thirty years of experience in innovative drug development, multiple drug research scientists with more than twenty years of experience in multinational pharmaceutical companies, and experts in clinical development and regulatory submissions in both China and the U.S. The team has a track record of successfully launching six innovative drugs.

【Investors】Joaquin Capital, Kangjun Capital, INFINITY CAPITAL, Hanking Capital

【CAR-T】Founded in 2015, Beijing Yimiaoshenzhou Medical Technology Co., Ltd., headquartered in Beijing and founded by alumni of Tsinghua University’s biology department, is a "hard technology" enterprise specializing in gene and cell-based drugs for the treatment of malignant tumors. The company adheres to independent innovation and owns a one-stop gene and cell drug technology and industrialization platform, mastering core technologies for the full-process production and preparation of CAR-T drugs. It has obtained seven IND approvals for Class 1 new CAR-T cell drugs and Beijing's first manufacturing license for gene and cell-based pharmaceuticals. Its core R&D pipeline covers hematological malignancies such as lymphoma, leukemia, and myeloma, solid tumors like liver cancer and colorectal cancer, as well as autoimmune diseases such as systemic lupus erythematosus. The company has undertaken more than ten national and provincial scientific research projects, collaborating with top-tier hospitals including Beijing Tumor Hospital, Tsinghua Changgung Hospital, Peking Union Medical College Hospital, Peking University Third Hospital, and Peking University People's Hospital on clinical research of CAR-T drugs. It has been accredited as a National High-tech Enterprise, a Postdoctoral Research Station, a Beijing Engineering Research Center, a Beijing specialized and new enterprise, and a joint CAR-T Research and Development Center.

【Investors】Taiping Healthcare Industry Equity Investment Fund, Sunshine Nuohua, Beijing-Tianjin-Hebei Coordinated Development Fund, Capital Technology Development Group

【Cell Therapy CDMO】Guangzhou Huishan Medical Technology Co., Ltd. is an innovative enterprise focused on the field of cell-based pharmaceuticals for immune diseases. It is committed to the research, development, and application of regenerative medicine technology using cellular therapies. With a focus on immune diseases as an entry point, the company aims to improve specialized disease prevention systems and precision diagnosis and treatment through its product development initiatives. It has strategically positioned itself in areas such as immune function testing, immune cell storage, drug development, and biomedically engineered cell-based pharmaceutical R&D. The goal is to build an immune cell regenerative medicine industry chain, providing new solutions to enhance the precision diagnosis and treatment of immune diseases. The company has received international ISO15189 accreditation for its medical testing laboratory standards. It has completed government project registrations for the "Lingnan International Comprehensive Cell Bank," "Lingnan Regional Cell Preparation Center," and "Lingnan Biotechnology Transformation and Application Platform." Additionally, the construction of its GMP-grade cell pharmaceutical manufacturing facility has been evaluated by the Guangdong Provincial Institute for Drug Control to meet “A+B”-level environmental standards.

【Investor】Guangzhou Jinyuan Shoujian Investment

【AAV Gene Therapy Drugs】Chengdu Jinweike Biotechnology Co., Ltd. is a biotechnology company dedicated to the development of AAV gene therapy new drugs for ophthalmic diseases, neuromuscular diseases, and genetic metabolic diseases. Currently, multiple AAV gene therapy products in its pipeline have entered the IIT clinical research stage. Under the leadership of Academician Yuquan Wei and researcher Yang Yang, the company has built a 3,000-square-meter R&D and production base that integrates AAV gene drug research and development, pilot-scale production, and quality control. It has formed a highly integrated and comprehensive AAV gene therapy "technology chain," with its gene therapy drug R&D capabilities and AAV preparation technology at a leading level in China. The AAV gene therapy products prepared by the company have completed clinical studies in more than 100 patients, demonstrating excellent safety and efficacy data. The company's core management team comes from well-known pharmaceutical companies, research institutions, and universities both domestically and internationally. The core technical team’s background covers AAV vector design, pilot production, quality research, and medical clinical work, endowing Jinweike with an integrated operational capability spanning the entire process from the original design of gene therapy products, scalable pilot production, to medical and clinical research.

【Investor】Donghu Investment, Sichuan Double Innovation Fund

【Innovative Drugs for Kidney Diseases】At the beginning of 2018, Alebund Pharmaceutical was incubated in Zhangjiang, Shanghai. As a biopharmaceutical company, Alebund is mainly committed to the discovery, development, manufacturing, and commercialization of innovative drugs for kidney diseases and related chronic conditions, providing better clinical treatment options for patients with chronic kidney disease (CKD) and related conditions worldwide. Since its establishment, the company has been recognized as a potential unicorn enterprise and a national-level technology-based small and medium-sized enterprise. Alebund Pharmaceutical has built a rich and balanced pipeline of new drugs for kidney diseases, including products targeting complications from CKD/dialysis, IgA nephropathy, diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), and autosomal dominant polycystic kidney disease (ADPKD). The company has completed and activated a small-molecule production base and established a specialized renal sales team responsible for the commercial promotion of related products in China.

【Investor】Yangzhou Guojin Investment, Xicheng Jinyun

【Stem Cell Regeneration of Platelets】Blood霁 Biotechnology is a stem cell biopharmaceutical company founded by returned overseas experts, dedicated to using stem cells to direct the regeneration of blood cells for cell therapy in various diseases and to carry out related drug research and development. The founding members of the company come from renowned universities both in China and abroad, such as Stanford University, Harvard University, and Peking University. Based on the world-leading system for the directed induction and differentiation of stem cells, the company’s lead product is platelets produced in vitro, addressing the urgent need for platelets in diseases like cancer, liver disease, critical emergencies, and blood disorders, while also developing innovative drugs for various platelet-related abnormalities. In addition, the company will focus on the in vitro regeneration of different cells derived from hematopoietic stem cells within the blood and immune systems, based on the globally advanced systems for the directed induction and differentiation of pluripotent stem cells (including embryonic stem cells and iPSC) and adult stem cells. These include platelets, red blood cells, macrophages, and NK cells, which are currently popular candidates for cell therapy and drug delivery. Furthermore, the company's unique non-viral, site-specific gene-editing technology is not only used for establishing and editing iPSC lines but also for efficiently inserting chimeric antigens into the genome.

【Investor】China Kangmei Medical Technology Group

【Ultrasound Imaging】Shenzhen Kunwei Technology Co., Ltd. is a professional ultrasound imaging equipment company that leads with breakthrough original technology and is committed to the development of next-generation high-definition, high-end ultrasound products, established in 2019. The company's unique kOS imaging platform utilizes distinctive full-state plane waves, SRBF super-resolution beam synthesis, and UP ultra-penetration probes, relying on powerful GPU processing capabilities to achieve an industry-first perfect combination of ultra-high penetration and deep resolution, producing deep super-resolution images. Super-resolution ultrasound imaging achieved on the kOS platform (SRUS) breaks the traditional mutual constraints among the three major parameters of ultrasound—spatial resolution, temporal resolution, and penetration—bringing a comprehensive revolutionary improvement to ultrasound imaging diagnostic performance. With an open and collaborative mindset, the company shares fundamental technical data and general code packages of its equipment, welcoming and assisting medical professionals with innovative ideas to independently develop unique functions on the Kunwei equipment platform, achieving shared success.

【Investors】Tencent Investment, Sherpa Investment, Qianhai Ark, Hengqin Jintou

【X-ray Imaging System】Lien Ability Era, founded in 2020, has a founding team with a strong technical background and deep industry experience. The company has built an integrated industrial chain encompassing research and development, production, sales, and service for core components of X-ray imaging systems, mastering a large number of leading core technologies. Its products cover a wide range, from large focal points to micro focal points, from soft X-rays to high penetrability, and are used in fields such as industrial inspection and medical applications, gaining widespread market recognition. X-rays refer to light with wavelengths ranging from 1pm-10nm, corresponding to an energy range of approximately 124eV-1.24MeV, with extremely strong penetration power. Compared to optical imaging, X-ray imaging allows for clear visualization of internal structures, offering good visibility, high resolution, and non-destructive characteristics. X-ray imaging is widely applied in areas like medical imaging, semiconductors, new energy, aerospace, and scientific research, with its applications continuing to expand.

【Investor】Hillhouse Ventures

【Medical Rehabilitation Robot】Fourier was founded in 2015 as a leading general robotics company, dedicated to creating highly intelligent universal robot platforms for real-world application scenarios, including medical rehabilitation and academic research. It has provided support and services to over 2,000 institutions and hospitals across more than 40 countries and regions worldwide. The company initially focused on medical rehabilitation exoskeleton robots and, through continuous technological iteration and innovation, launched more than 30 rehabilitation robot products covering all aspects of movement rehabilitation needs. It introduced the "Intelligent Rehabilitation Port" as an integrated rehabilitation solution platform, with intelligent rehabilitation robot training at its core. Through standardized interfaces and complementary robotic configurations, it achieves multi-robot collaboration, data interconnection, and intelligent management, significantly improving rehabilitation efficiency. In terms of general humanoid robots, Fourier has launched two products: GR-1 and GR-2, which cover application scenarios such as tour guidance, academic research, and medical rehabilitation. These robots feature a highly biomimetic torso configuration and anthropomorphic motion control, with up to 54 degrees of freedom across the body, enabling functions like fast walking, agile obstacle avoidance, stable slope traversal, and resistance to impact disturbances. Fourier Intelligence has established a comprehensive product line tailored for rehabilitation institutions, offering high-performance rehabilitation robots, intelligent rehabilitation products, physical therapy equipment, and digital and intelligent rehabilitation solutions to customers worldwide. The company's headquarters is located in Zhangjiang, Shanghai, with a regional headquarters in Singapore. R&D and production facilities are set up in Beijing, Shanghai, Guangzhou, Zurich, and Chicago, forming a global network for R&D, manufacturing, and service.

【Investor】Junshan Capital, Prosperity7 Ventures, Zhangjiang Sci-Tech Investment, Pudong Venture Capital, Guoxin Investment

[Digital PCR]Suzhou RainSure Biotech Co., Ltd. moved into Suzhou BioBay in July 2017. The founding team members are Ph.D. holders from Ivy League schools and top universities in the United States, with strong academic backgrounds and extensive industrial experience. The core team has worked for well-reputed, long-established biotech companies in the industry, participating in and leading the development of several well-known products multiple times. Since its establishment, RainSure Biotech has secured tens of millions of yuan in investments from prominent Chinese investment institutions such as ZhenFund, Volcanic Stone Capital, and Ming Shi Capital. RainSure Biotech also won the championship of the Western U.S. division in the first overseas entrepreneurship competition organized by the China Association for Science and Technology. Currently, RainSure has successfully launched several products, including the DropX-2000 digital PCR system and more than 50 RUO test kits. These products have been used by numerous enterprises and research users and have received widespread acclaim. The company integrates microfluidics, optics, precision instrumentation, electronic engineering, and biochemistry to focus on the research and development of equipment systems in the fields of molecular diagnostics and genetic testing.

【Investors】Ruijiang Kangsheng Fund

【AI+ Disease Management】Since its establishment on September 9, 2015, Weimai has continuously promoted the digital upgrade of healthcare services, empowered medical institutions and healthcare professionals, and provided comprehensive, full-cycle medical and health services to the entire population, meeting the multi-level, diversified, and personalized service needs of the people. As the pioneer of AI + full disease management, Weimai has become China's largest full disease management service platform, driving the large-scale application of full disease management through its self-developed CareAl artificial intelligence technology. Committed to building a managed care organization (MCO) with Chinese characteristics, Weimai has received hundreds of millions of dollars in financing from major capital giants such as Yuanjing, Source Code, Jingwei, Qianji, IDG, Baidu Capital, and CCB Investment. It is one of the representatives of high-tech, high-growth, and high-value unicorn companies in the current digital health field, widely recognized by the government, industry, and users. Weimai’s services cover 30 provinces, municipalities, and autonomous regions in China, are available in over 280 cities, have partnerships with more than 2,500 hospitals, serve over 60 million users, and have provided cumulative services exceeding 1 billion times. Additionally, 200,000 doctors offer more than 20,000 types of medical and health service SKUs on Weimai.

【Investor】CITIC Investment, Qiushi Capital, Nanhu Equity Investment Fund, Source Code Capital, Qianji Capital, Yuanjing Capital, Deqing Industrial Investment Fund, Yuhang State Investment Group

【AI+Dental SaaS】Founded in 2015, LeadLink is headquartered in Shanghai and has established more than 20 branches across China. The company owns 100 software copyrights, 91 registered trademarks, and 35 invention patents. It is committed to providing integrated business management solutions for consumer healthcare enterprises such as dental clinics and medical aesthetics institutions. The company innovatively adopts the SaaS+X model and operates several brands including e-KanYa Software, e-KanYa Mall, and LeadLink YUEJIAN. e-KanYa Software provides SaaS services covering the entire business process for dental institutions, including single-store/chain management, electronic medical records, customer relationship management, inventory management, intelligent marketing, BI (Business Intelligence) analysis, and imaging integration. e-KanYa Mall connects over 1,000 well-known domestic and international consumables brands upstream in the industry chain and offers nearly 20,000 rigorously selected consumables products, providing one-stop procurement services for dental institutions. LeadLink YUEJIAN, guided by the concept of "precise diagnosis, precise orthodontics, and precise monitoring," is a new-generation invisible orthodontic solution provider. It has launched multiple product series, including YUEJIAN Adult Orthodontics and YUEYA Children's Early Orthodontics.

【Investors】Wuxi Venture Capital, Binhu Industrial Group

【Pet Vaccines】AI Yi Animal Pharmaceuticals is a leading pet vaccine company in China, dedicated to the research, registration, and production of pet vaccines with international top-tier quality. It aims to address the long-standing issues of limited variety and strain matching in China's pet vaccine market. Its product pipeline covers key pet vaccine varieties that are currently lacking in China, globally innovative vaccines targeting both Chinese and international markets, as well as localized alternatives and upgraded versions of existing imported pet vaccines. The founder and president of the company, Dr. Zhu Xianzhu, has previously served as Executive Vice President, Chief Scientific Officer, Chief Biologics Officer, and Global Head of R&D at multinational corporations such as Fort Dodge Animal Health, Pfizer Animal Health (now Zoetis), Elanco Animal Health, and Ceva Animal Health. The AI Yi Animal Pharmaceuticals team, which he has built and led, has cumulatively developed and registered hundreds of animal vaccines and drugs, making it one of the most experienced and accomplished teams in the global pet vaccine field. The company’s most advanced product in terms of R&D and registration progress is the canine Bordetella bronchiseptica vaccine (mucosal immunity), commonly referred to as the kennel cough vaccine, Bb Vaccine. Internationally, this is an important vaccine for dogs, used to prevent respiratory diseases such as coughing and wheezing caused by Bordetella bronchiseptica infection, as well as severe illness and death. Additionally, the company is developing globally innovative pet vaccines such as reproductive control vaccines (also known as "sterilization vaccines").

【Investor】Rehabilitation Capital, National Development Venture Capital, Kunshan Taiwanese Business Development Investment Fund